Cantel Medical : January 2016 - Cantel Investor Overview

Slide 1

January 2016 / Investor Presentation‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌‌

NYSE:CMN

NYSE:CMN

FORWARD LOOKING STATEMENT

This document contains "forward-looking statements" - that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," or "target." Forward-looking statements - such as statements about our revenues; income; organic growth; acquisition strategy; and five-year strategic plan - are generally based on current estimates and forecasts. By their nature, forward looking statements address matters that are, to different degrees, subject to a risks, uncertainties and factors that could cause our actual results to be materially different than those expressed in such statements. Many of the material risks, uncertainties and factors are described in "Risk Factors" in our Annual Report on Form 10-K for the year ended July 31, 2015 and filings with the Securities and Exchange Commission. We do not intend, or assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated.

This document also contains non-GAAP financial information. Management uses this information in its internal analysis of results and believes that this information may be informative to investors in gauging the quality of our financial performance, identifying trends in our results and providing meaningful period-to-period comparisons. For a reconciliation of non-GAAP measures presented in this document, see the accompanying appendix.

Cantel Medical is a NYSE leader in Infection Prevention & Control (IP&C)

$582

MILLION1

Sources of strength

Leading pure-play in the growing $50B global IP&C market with existing businesses in addressable markets of

~$6B

Government / industry focus on IP&C is a growth driver, shielding our markets from weak economic cycles

We lead

in every major category where we compete

Strong financial performance

for more than

Proven expertise in identifying, executing and integrating acquisitions

10 YEARS

27 ACQUISITIONS

since 2000